Top Court Mandated Review Leads to Immediate Ban on 16 'No Therapeutic Value' Drug Combinations
The Ministry of Health and Family Welfare has issued an order under Section 26A of the Drugs and Cosmetics Act, 1940, banning the manufacture, sale, and distribution of 16 Fixed Dose Combination (FDC) drugs with immediate effect. The decision follows a scientific review that found these formulations lack therapeutic justification and may pose risks to public health.
This action stems from a Supreme Court-mandated review of the Indian drug market. The court directed the Drugs Technical Advisory Board (DTAB) to form an expert committee to identify potentially harmful or irrational drug combinations. After examining clinical data, the panel concluded that these 16 specific FDCs offer no real therapeutic value to patients, leading to the current prohibition.
Fixed Dose Combinations are medicines that contain two or more active ingredients in a single dosage form. While some FDCs are beneficial for improving patient compliance or enhancing efficacy, the banned combinations were found to be irrational, with no added benefit over individual components taken separately. The expert committee determined that continuing their availability could expose patients to unnecessary side effects without corresponding therapeutic advantage.
The ban covers a range of commonly used FDCs, including antibiotics, analgesics, and cough syrups. The government has directed all manufacturers, distributors, and retailers to cease production, sale, and distribution immediately. Any non-compliance may attract legal action under the Drugs and Cosmetics Act.
This move aligns with ongoing efforts by the Indian government to rationalize drug usage and ensure that only safe and effective medicines remain in the market. Previous bans have targeted other irrational FDCs, including those containing combinations of paracetamol with certain painkillers and antibiotics with antacids. Public health experts have welcomed the decision, noting that removing ineffective drug combinations reduces the risk of antimicrobial resistance and adverse drug reactions.
Patients currently using any of the banned FDCs are advised to consult their healthcare providers for alternative treatments. The Ministry has emphasized that the ban is precautionary and based on evidence, urging the public not to stockpile or use these products.
